Delivery of CD47 blocker SIRPα-Fc by CAR-T cells enhances antitumor efficacy

BACKGROUND: Chimeric antigen receptor (CAR) T cell therapy has been successfully applied in treating lymphoma malignancies, but not in solid tumors. CD47 is highly expressed on tumor cells and its overexpression is believed to inhibit phagocytosis by macrophages and dendritic cells. Given the antitu...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Huanpeng, Yang, Yuying, Deng, Yuqing, Wei, Fengjiao, Zhao, Qingyu, Liu, Yongqi, Liu, Zhonghua, Yu, Bolan, Huang, Zhaofeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Immune Cell Therapies and Immune Cell Engineering
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8811602/
https://www.ncbi.nlm.nih.gov/pubmed/35110357
http://dx.doi.org/10.1136/jitc-2021-003737

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8811602/
https://www.ncbi.nlm.nih.gov/pubmed/35110357
http://dx.doi.org/10.1136/jitc-2021-003737

Ejemplares similares